Avn Medical Marijuana (AM) is a new program in Australia that aims to help people with medical conditions such as epilepsy or depression.
It allows people to apply for a permit and receive medical cannabis oil through an online portal.
The program allows for patients to access their prescription and then to apply to be reimbursed for the cost of cannabis and other medical treatments.
But the company has faced some serious problems, and has faced regulatory concerns over the past few years.
A new report by the Australian Institute of Health and Welfare (AIHW) has been issued for the first time, and outlines a range of problems with the program, including its lack of transparency and lack of any accountability.
The report, which was issued on Tuesday, outlines the company’s problems with AM as well as how the system is set up, which is where the problems lie.
Here’s what you need to know about AM and how it works.
What is AM?
AM is a licensed medical cannabis producer and distribution company.
It operates out of three Australian locations: Brisbane, Adelaide, and Perth.
In 2018, AM was granted a permit to grow cannabis in Queensland, while in 2019, the company also expanded its operations to New South Wales.
AM has a number of partners, but they are the only licensed producers of cannabis in Australia.
AM is also a cannabis delivery company, which means it sells cannabis to individuals who need it, and it sells it via licensed dispensaries.
AM’s partners are Meds, a private pharmaceutical company, and the Australian Medicines and Healthcare Products Regulatory Agency (AMHRPA).
AMHRPA is Australia’s regulator of cannabis, and is charged with overseeing the health and safety of cannabis products.
It has strict rules around the quality and safety requirements for medical cannabis, as well being responsible for ensuring the supply chain for AM’s products.
The company was granted the ability to grow and supply cannabis in New South a few years ago, and now it has the opportunity to grow in Queensland.
How does AM work?
The AM program is set-up so that patients can get their cannabis oil via a program called “diligence program,” which allows people with specific conditions to apply, and receive a license for the costs of cannabis.
The first patient to apply gets a permit, and then they are given access to cannabis.
In order to get the permits, people need to pay a $30 application fee, which can be waived if they meet certain criteria.
AM also has a “supply program” that allows people who need their cannabis to purchase it.
This program allows people and companies to purchase cannabis through a secure online portal, where they are able to get their prescription filled.
These supplies can be bought through the portal, or through a retail store.
The supply program also allows people that are registered in a CBD, a specific section of CBD where people can grow cannabis, to buy it.
In other words, the supply program is a mechanism that allows individuals with specific medical conditions to obtain cannabis at the least cost to them.
However, AM doesn’t have any formal process for patients, and does not take any responsibility for ensuring that their prescription is filled, or their supply is approved.
What do the problems with it say about AM?
The company’s biggest problem is that AM doesn.
AM suffers from a range to its website, which includes a number problems with its transparency.
The website is broken up into several sections, which have separate pages for each section.
For example, the section for “medical cannabis,” has a section on the state of the state, as if it were a one-page newspaper article.
The section for the “supplies” section is broken down into a number pages, each with their own section.
One page has the company logo, which appears above a number that represents the number of permits.
The sections are then labelled with the product type, the CBD location, and a link to the cannabis supplier’s website.
The only section where there is a link back to the CBD website is for the CBD program, which says “If you need more information about CBD, contact us.”
AM is so vague about the program that it makes it difficult for anyone who doesn’t know what they’re talking about to find out.
There is no indication on the company website that any patients are eligible for the program.
One of the main complaints about the company is that it doesn’t take any accountability for its actions, as AM only discloses the number and location of its partners and provides no details of the program itself.
The problem is compounded by the fact that AM only publishes the information it provides.
AM only provides the information that it receives from its partners.
It doesn’t make a distinction between its partners who are registered and unregistered, or between those who are receiving medical cannabis and those who aren’t.
This means that there is no way of knowing whether patients with specific types of conditions are receiving cannabis from an approved supplier, or whether